HF
VKTX icon

HRT Financial’s Viking Therapeutics VKTX Stock Holding History

HRT Financial’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-60,300
Closed -$1.96M – 5437
2026
Q1 		$1.96M Buy
+60,300
New +$1.94M ﹤0.01% 1627
2025
Q4 		– Sell
-154,100
Closed -$4.05M – 4114
2025
Q3 		$4.05M Buy
+154,100
New +$4.6M 0.01% 784

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

HRT Financial's VKTX Position: Q2 2026 in Review

HRT Financial opened a new position in Viking Therapeutics (VKTX) in Q2 2026: 105,667 shares worth $4.12M. The stake represents 0.01% of the portfolio and ranks #1263 among its holdings. This is a return to the name: HRT Financial previously reported a position in VKTX as recently as Q3 2025.

HRT Financial first reported a position in VKTX in Q4 2018 and has held it in 15 quarters since. The position peaked at $21M in Q2 2024. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • HRT Financial held 105,667 shares of Viking Therapeutics worth $4.12M as of Q2 2026.
  • Viking Therapeutics was a new HRT Financial position in Q2 2026.
  • Viking Therapeutics made up 0.01% of HRT Financial's portfolio in Q2 2026, its #1263 holding.
  • HRT Financial first reported a position in Viking Therapeutics in Q4 2018 and has held it in 15 quarters since.
  • HRT Financial's Viking Therapeutics position peaked at $21M in Q2 2024.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.